Lilly's Emgality launch paving the way for a pain franchise: exec by Eric Sagonowsky Wednesday, January 9, 2019 Despite its CGRP drug Emgality's third-to-market status, Lilly has big plans for a growing stable of migraine and pain drugs, an exec said.
Lilly’s strong Q1 cushions FDA thumbs-down on 4-mg baricitinib by Arlene Weintraub Tuesday, April 24, 2018 Lilly analysts worry growth could suffer if it doesn't win a nod for both baricitinib doses—and an FDA panel shot down one of them Monday.
Eli Lilly counts up 2300 early retirements in cost-cutting drive by Eric Sagonowsky Thursday, November 9, 2017 With more than 2,000 early retirements settled, Eli Lilly says it's "on track" to hit its goal of cutting 3,500 jobs by year's end.
In second exec shake-up, Lilly loses longtime R&D chief by Arlene Weintraub Friday, September 29, 2017 Lilly CEO David Ricks has overhauled his team twice since he took over in January, and this time he's focusing on manufacturing, tech and R&D.
Lilly shakes up exec ranks as part of commercial overhaul by Tracy Staton Thursday, January 5, 2017 At Eli Lilly, the new year comes with a shakeup in its commercial organization, with vet Enrique Conterno taking the reins in the U.S. and ex-Novartis exec Christi Shaw joining as head of Bio-Medicines.
